SGP SPYGLASS PHARMA INC revenue, earnings and financials
For the quarter ended June 30, 2026, SPYGLASS PHARMA INC reported revenue of n/a, net income of −$19.9M and diluted EPS of −$0.59; for the fiscal year ended December 2025 revenue was n/a.
SGP annual revenue and earnings
- Fiscal year ended Dec 2025: revenue n/a, gross profit n/a, operating income −$41.4M, net income −$39.9M (margin n/a), EPS −$17.98
- Fiscal year ended Dec 2024: revenue n/a, gross profit n/a, operating income −$27.1M, net income −$29.2M (margin n/a), EPS −$16.31
SGP quarterly revenue and earnings
- Quarter ended Jun 30, 2026: revenue n/a, net income −$19.9M, EPS −$0.59
- Quarter ended Mar 31, 2026: revenue n/a, net income −$13.8M, EPS −$0.69
- Quarter ended Jun 30, 2025: revenue n/a, net income −$8.68M, EPS −$3.81
- Quarter ended Mar 31, 2025: revenue n/a, net income −$8.82M, EPS −$3.96
SGP cash flow, buybacks and dividends
- Fiscal year ended Dec 2025: operating cash flow −$32.7M, share buybacks $1.45M
- Fiscal year ended Dec 2024: operating cash flow −$22.0M, share buybacks $0
SGP balance sheet
- Jun 30, 2026: cash $223M, total assets $243M, total liabilities $11.1M, shareholders' equity $232M
- Mar 31, 2026: cash $239M, total assets $258M, total liabilities $8.27M, shareholders' equity $250M
- Dec 31, 2025: cash $96.4M, total assets $116M, total liabilities $10.2M, shareholders' equity −$98.8M
- Dec 31, 2024: cash $16.3M, total assets $23.3M, total liabilities $11.2M, shareholders' equity −$60.5M
Is SGP profitable?
No. SPYGLASS PHARMA INC lost $39.9M in its latest fiscal year.